Evidence map›Paper›PMID 39409145›Full record

ArticleInternational journal of molecular sciences2024

Leveraging Therapeutic Proteins and Peptides from

Nasser Alotaiq, Doni Dermawan, Nasr Eldin Elwali

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Molecular pain
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nasser AlotaiqHealth Sciences Research Center, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11432, Saudi Arabia.ORCID 0009-0005-8709-8710
Doni DermawanDepartment of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.ORCID 0000-0003-2545-1775
Nasr Eldin ElwaliDivision of Biochemistry, Research Center for Health Sciences, Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University, Riyadh 11432, Saudi Arabia.ORCID 0000-0002-1876-0687

Funding

Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU) 221413005
6 · The paper itself

Abstract

Suppressor of cytokine signaling 2 (SOCS2), an E3 ubiquitin ligase, regulates the JAK/STAT signaling pathway, essential for cytokine signaling and immune responses. Its dysregulation contributes to cardiovascular diseases (CVDs) by promoting abnormal cell growth, inflammation, and resistance to cell death. This study aimed to elucidate the molecular mechanisms underlying the interactions between

Indexed as

Cardiovascular DiseasesMolecular Docking SimulationMolecular Dynamics SimulationOligochaetaPeptidesSuppressor of Cytokine Signaling ProteinsAnimalsHumansProtein BindingUbiquitin-Protein LigasesPeptidesSuppressor of Cytokine Signaling ProteinsUbiquitin-Protein Ligasescardiovascular diseaseearthwormlumbrokinasemolecular dynamics simulationprotein–protein interactionsSOCS2

Identifiers

PMID39409145
PMCPMC11477351

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.